Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

3-(5-chloro-2-oxobenzo[d]oxazol-3(2H)-yl) propanoic acid derivatives as kmo inhibitors

a technology of oxazol and derivatives, applied in the field of new drugs, can solve the problems of rapid progression to multiple organ dysfunction (mod), and no effective treatment availabl

Inactive Publication Date: 2016-11-03
GLAXOSMITHKLINE INTPROP DEV LTD
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent describes a compound of formula (I) or a pharmaceutically acceptable salt thereof that can be used as a medicament. The compound has various substituents such as X, R1, m, n, and R2, and can be used to treat various conditions such as pain, inflammation, and cancer. The patent also provides a pharmaceutical composition containing the compound and a carrier. Overall, this patent provides a compound with versatility and potential to improve patient outcomes.

Problems solved by technology

However for the remaining 20-30% of patients a systemic inflammatory response occurs, resulting in rapid progression to multiple organ dysfunction (MOD).
Despite this high unmet need and the seriousness of the disease, there are no effective treatments available, with current standard of care being purely supportive.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 3-(5-chloro-2-oxobenzo[d]oxazol-3(2H)-yl) propanoic acid derivatives as kmo inhibitors
  • 3-(5-chloro-2-oxobenzo[d]oxazol-3(2H)-yl) propanoic acid derivatives as kmo inhibitors
  • 3-(5-chloro-2-oxobenzo[d]oxazol-3(2H)-yl) propanoic acid derivatives as kmo inhibitors

Examples

Experimental program
Comparison scheme
Effect test

example 1

3-(5-Chloro-6-methyl-2-oxobenzo[d]oxazol-3(2H)-yl)propanoic acid

[0503]

[0504]5-Chloro-6-methylbenzo[d]oxazol-2(3H)-one (Intermediate 3, 150 g, 0.82 mol), 3-bromopropanoic acid (251 g, 1.64 mol), potassium carbonate (226 g, 1.64 mol) were mixed in acetonitrile (2 L) and the reaction mixture stirred at 80° C. for 18 h. The reaction mixture was cooled to ambient temperature and filtered. The solid was collected and acidified to pH 4-5 with hydrochloric acid (3 N) and extracted with ethyl acetate (300 mL×5). The combined organic phases were dried over sodium sulphate, filtered, the filtrate was collected and the solvent evaporated to give 3-(5-chloro-6-methyl-2-oxobenzo[d]oxazol-3(2H)-yl)propanoic acid as a yellow solid (220 g). Used without further purification.

[0505]1H NMR (300 MHz, d6-DMSO) δ 12.43 (bs, 1H), 7.51 (s, 1H), 7.36 (s, 1H), 4.00 (t, J=6 Hz, 2H), 2.70 (t, J=6 Hz, 2H), 2.33 (s, 3H).

example 1 (

Alternative Preparation)

3-(5-Chloro-6-methyl-2-oxobenzo[d]oxazol-3(2H)-yl)propanoic acid

[0506]

[0507]A mixture of 5-chloro-6-methylbenzo[d]oxazol-2(3H)-one (250 mg, 1.362 mmol, commercial), potassium carbonate (565 mg, 4.09 mmol) and 3-bromopropanoic acid (417 mg, 2.72 mmol) in acetonitrile (10 mL) was heated to 90° C. and stirred for 2 h. The mixture was cooled and filtered; the isolated white powder was washed with acetonitrile, suspended in water and acidified to pH 2 with hydrochloric acid (1N). The resulting solid was then triturated with hot acetonitrile, filtered and dried to give the 3-(5-chloro-6-methyl-2-oxobenzo[d]oxazol-3(2H)-yl)propanoic acid as a white powder (225 mg, 64.6%).

[0508]LCMS (E): Rt 2.29 min, [M-H]− 254 / 256

Example 1a Tris Salt Formation

3-(5-chloro-6-methyl-2-oxobenzo[d]oxazol-3(2H)-yl)propanoic acid, 2-Amino-2-(hydroxymethyl)-1,3-propanediol salt

[0509]

[0510]A mixture of 3-(5-chloro-6-methyl-2-oxobenzo[d]oxazol-3(2H)-yl) propanoic acid (Example 1, 220 g, 0.863...

example 2

3-(5-chloro-2-oxo-6-(1-(pyridin-2-yl)ethoxy)benzo[d]oxazol-3(2H)-yl)propanoic acid, 2-Amino-2-(hydroxymethyl)-1, 3-propanediol salt

[0513]

[0514]Methyl 3-(5-chloro-2-oxo-6-(1-(pyridin-2-yl)ethoxy)benzo[d]oxazol-3(2H)-yl)propanoate (Intermediate 12, 270 mg) in hydrochloric acid (0.5 N, 5 mL) was added to 1,4-dioxane (5 mL) and the reaction mixture was stirred at 80° C. for 3 h. The solvent was removed, the residue was purified by prep-HPLC [eluent: MeCN-water (0.1% TFA), gradient: 60-90% MeCN] to give 3-(5-chloro-2-oxo-6-(1-(pyridin-2-yl)ethoxy)benzo[d]oxazol-3(2H)-yl)propanoic acid as a yellow oil (30 mg, 0.08 mmol). Methanol (2 mL) and 2-amino-2-(hydroxymethyl)-1, 3-propanediol (10 mg, 0.08 mmol) were added and the reaction mixture was stirred at room temperature for 30 minutes. The mixture was concentrated to give 3-(5-chloro-2-oxo-6-(1-(pyridin-2-yl)ethoxy)benzo[d]oxazol-3(2H)-yl)propanoic acid, 2-Amino-2-(hydroxymethyl)-1, 3-propanediol salt as a yellow oil (40 mg, 17%).

[0515]LCMS...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Pharmaceutically acceptableaaaaaaaaaa
Login to View More

Abstract

A compound of formula (I) or a salt thereof are provided:wherein R1, X and R3 are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

Description

FIELD OF THE INVENTION[0001]The present invention relates to novel 5-chlorobenzo[d]oxazol-2(3H)-one derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.BACKGROUND OF THE INVENTION[0002]Kynurenine monooxygenase (KMO) is a flavin adenine dinucleotide (FAD) dependent monooxygenase located on the outer mitochondrial membrane. KMO is known to oxidise L-Kynurenine (KYN) to 3-hydroxykynurenine (3HK) as part of the major route of catabolism of tryptophan. 3HK is then converted to 3-hydroxyanthranilic acid and quinolinic acid by kynureninase (KYNU) and 3-hydroxyanthranilate 3,4-dioxygenase (3-HAAO).[0003]KMO is highly expressed in tissues including the liver, placenta, kidney [Alberati-Giani, FEBS Lett. 410:407-412(1997)] endothelial cells and monocytes and at a lower level in microglia and macrophages in the brain.[0004]Increased levels of 3HK and quinolinic acid and red...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D263/58C07C215/10C07C211/27C07C211/13C07C279/14C07C229/26C07C309/30C07D413/12C07C223/02
CPCC07D263/58C07D413/12C07C215/10C07C211/27C07C211/13C07C279/14C07C229/26C07C309/30C07C223/02A61P1/00A61P1/04A61P1/16A61P1/18A61P11/00A61P13/12A61P17/02A61P21/00A61P25/00A61P25/14A61P25/16A61P25/18A61P25/24A61P25/28A61P31/04A61P31/12A61P37/02A61P43/00A61P9/00A61K31/423A61K31/4439A61K31/501A61K31/506
Inventor BOUILLOT, ANNE MARIE JEANNEMIRGUET, OLIVIERLIDDLE, JOHNWALKER, ANNE LOUISE
Owner GLAXOSMITHKLINE INTPROP DEV LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com